Swift Health Systems Inc, Irvine, Calif, makers of INBRACE, announced the company has raised $45 million in series C funding to help bolster commercialization of the bracket and wire system.
According to a press release from the company, the series C funds will be directed at broadening commercial availability of INBRACE through expanded orthodontist on-boarding and training, increased sales and marketing resources, and consumer demand generation programs to support existing and new INBRACE providers.
The company is positioning itself as an alternative to do-it-yourself (DIY) aligner therapy. INBRACE offers consumers and orthodontists a discrete and aesthetic solution that requires supervised treatment.
“INBRACE is a real game-changer, and this latest funding will help us ensure that every INBRACE provider can finally give their patients what they’ve always wanted – a truly invisible journey to a great new smile that is convenient and shows immediate results,” said Dr John Pham, CEO and co-founder of Swift Health Systems. “Even with DIY orthodontic therapy on the rise, most consumers appreciate the benefits of supervised healthcare from a licensed professional. INBRACE keeps patient care in the hands of clinicians, where the overall patient experience, oral health and treatment results are always top priorities.”
INBRACE lingual braces feature an all-digital platform. Patented INBRACE Smartwires are programmed using data captured from digital scans of patient teeth and automate many steps in orthodontic treatment. According to the company, the INBRACE system allows patient anatomy to naturally dictate the most efficient path for all tooth movement.
Financing was co-led by Vivo Capital, Novo Holdings, and venBio Partners. The board will include Andrew D. Goldberg, MD, principal at Vivo Capital; Peter Moldt, PhD, partner at Novo Ventures; and Aaron Royston, MD, partner at venBio.